TELA Bio TELA 深 沪
等待开盘 10-07 09:30:00 美东时间
1.09
-0.050
-4.39%
华盛通- 最 高1.2974
- 今 开1.12
- 成交量 14.63万股
- 最 低 1.09
- 昨 收 1.14
- 总市值 4.92万
- 52周最高 1.56
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 0.5011
- 委 比 9.74%
- 总股本 4.51万
- 历史最高 23.545
- 量 比 0.74
- 振 幅 18.19%
- 历史最低 0.5011
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TELA Bio gains short-term relief on loan covenants
The latest update is out from TELA Bio ( ($TELA) ). On September 28, 2026, TELA...
09-30 04:35
美股大行评级 | Meta获4家机构看好！目标价最高升至950美元；好市多绩后齐遭机构降低目标价
今日重点评级关注：古根海姆：维持Damora Therapeutics"买入"评级，目标价从40美元升至60美元；HC Wainwright & Co.：维持Rezolute"买入"评级，目标价从5美元升至10美元
09-28 12:37
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2
Craig-Hallum analyst Chase Knickerbocker initiates coverage on TELA Bio (NASDAQ:TELA) with a Buy rating and announces Price Target of $2.
09-26 00:21
TELA Bio Implements Workforce Cuts and Leadership Changes
An update from TELA Bio ( ($TELA) ) is now available. On August 28, 2026, TELA ...
08-31 19:28
TELA Bio COO And CFO Roberto Cuca To Step Down Effective Immediately
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today.
08-31 19:09
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
TELA Bio announced the departure of COO and CFO Roberto Cuca and launched a cost-cutting initiative to reduce annual operating expenses by $17 million (18%) through a 20% headcount reduction and streamlined external resources. The company expects the measures to extend its cash runway into 2028, with a one-time restructuring charge of $1.5 million in Q3 2026.
08-31 11:00
TELA Bio shares are trading lower after the company reported worse-than-expected Q2 financial results.
TELA Bio shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 02:15
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. announced that its Board of Directors approved inducement grants of stock options and restricted stock units to its newly-hired Chief Executive Officer, Heather Getz, and 11 new employees. The grants include options to purchase 2,370,000 shares and restricted stock units covering 500,000 shares for Ms. Getz, as well as restricted stock units for 95,500 shares for the new employees. The stock options have an exercise price of $0.74 ...
08-05 20:05
TELA Bio Appoints Heather Getz CEO, Effective Immediately
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the "Board") has appointed Heather Getz as Chief Executive Officer and Director, effective today.
08-04 19:11
TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TELA Bio, Inc. (NASDAQ: TELA) announced its participation in the Canaccord Genuity 46th Annual Growth Conference, with management scheduled to present on August 12, 2026, at 8:30 am ET. The live and archived webcast will be available at ir.telabio.com. TELA Bio specializes in innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation and minimize synthetic material exposure. For more information, visit www.telabi...
07-29 20:05
